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The influence of pharmacotherapeutic follow-up (PTF) on quality of life was evaluated in 45 HIV+ 
patients, who were undergoing initial antiretroviral therapy at a specialized care center in northeast 
Brazil. PTF lasted nine months and quality of life was analyzed at the 1st and 9th meetings using a 
questionnaire validated for Brazil. The study identified 643 problems related to antiretrovirals and 
there were 590 pharmaceutical interventions during the PTF. The comparative analysis between the 
results of the 1st and the 9th meeting was statistically significant for all domains of the questionnaire. 
For asymptomatic patients, only one domain was statistically significant. For symptomatic patients, six 
domains were significant. Patients with one year of HIV/AIDS diagnosis had statistically significant 
differences in five domains. The results suggest that the PTF contributed to improving quality of life, 
particularly for symptomatic patients and those diagnosed for at least one year – important target groups 
for Pharmaceutical Treatment.
Uniterms: Pharmacotherapeutic follow-up/influence/quality of life. HIV patients/quality of life. 
Pharmaceutical care.
A influência do seguimento farmacoterapêutico (SFT) sobre a qualidade de vida foi avaliada em 45 
pacientes HIV+ assistidos em serviço de atendimento especializado do nordeste brasileiro. O SFT teve 
duração de 9 meses e a qualidade de vida foi analisada no 1° e 9° encontros através de questionário 
validado no País. Identificaram-se 643 problemas relacionados aos antirretrovirais e realizaram-se 590 
intervenções farmacêuticas durante o SFT. A análise comparativa entre os resultados de qualidade de 
vida do 1° e 9° encontro foi estatisticamente significativa em todos os domínios do questionário. Quando 
analisados somente os pacientes assintomáticos, apenas um domínio apresentou significância estatística. 
Entre os sintomáticos, seis domínios foram significativos. Pacientes com até um ano de diagnóstico de 
HIV/AIDS apresentaram validade estatística em cinco domínios. Os resultados sugerem que o SFT 
contribuiu para a melhoria da qualidade de vida dos pacientes, sobretudo dos sintomáticos e/ou com até 
um ano de diagnóstico, representando grupos-alvo para a prática da Atenção Farmacêutica. 
Unitermos: Seguimento farmacoterapêutico/influência/qualidade de vida. Paciente de HIV/qualidade 
de vida. Atenção Farmacêutica.
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INTRODUCTION
The first case of AIDS, a disease caused by the 
human immunodeficiency virus (HIV), was identified 
over 25 years ago; since then, there has been a significant 
decrease in morbidity and mortality among HIV-infected 
people as a result of improvement in access to care, pro-
phylaxic treatment for opportunistic infections and anti-
retroviral therapy (ART) (Aberg et al.,2009).
The Brazilian STD/AIDS program has become 
internationally recognized for its widespread use of, and 
access to, antiretroviral therapy, and for the improvements 
it has achieved in the indicators of morbidity, mortality and 
quality of life. However, the profile of the disease has now 
become chronic-degenerative (Brasil, 2008).
Although ART has undoubtedly positive effects (it 
promotes a profound and constant suppression of HIV 
replication, restores immune function, reduces morbidity 
and mortality and promotes positive therapeutic outcomes 
for patients infected with HIV (Palella et al., 1998), there 
are numerous factors that can hamper the achievement 
of desired goals, including the pathogenicity of the virus 
strain, a patient’s basal levels, the appearance of resistance 
and non-adherence to treatment (Chesney, Morin, Sherr, 
2000; Bartlett, 2002). Additionally, some people that have 
received antiretroviral therapy for a long period, live with 
the effects of drug toxicity such as lipodystrophy, and co-
infections - Hepatitis B or C - (Brasil, 2008).
Antiretroviral treatment has many factors that can 
hinder adherence: the use of more than one drug, a regi-
men involving more than one dose per day, the presence 
of adverse effects, prolonged treatment and asymptom-
atic patients (Chesney, Morin, Sherr, 2000; Walsh et al., 
2001). These drawbacks of antiretroviral therapy directly 
interfere with the quality of life of HIV-infected patients.
According to the literature review by Canini et al. 
(2004), most studies that assess quality of life have been 
developed in the U.S. or developed countries; however, in 
recent years, scientists have recognized the need for world-
wide research on this subject, including in Brazil, where 
epidemiological data have shown a significant number of 
people are affected by this disease.
In 2003, the American Society of Health-System 
Pharmacists (ASHP) produced a document with recom-
mendations for the main fields of pharmacist practice 
within the health care team, emphasizing the pharmacist’s 
role in the care of patients with HIV infection. 
Among the recommendations are: 1. Systematic 
evaluation of interactions, adherence and adverse effects; 
2. Actions related to the monitoring process of pharma-
cotherapy, with the detection, prevention and resolution 
of other problems related to drug indication, effectiveness 
and safety; 3. Recognition and prevention of opportunistic 
infections and other potential clinical complications; 4. 
Education and prevention in public health, and 5. Forward-
ing of information and recommendations on the correct 
use of antiretroviral drugs, emphasizing the process of 
taking these drugs.
These recommendations constitute one of the areas 
of pharmaceutical professional practice: Pharmaceutical 
Care. Pharmacotherapeutic follow-up, one of the macro-
components of Pharmaceutical Care, is carried out by the 
pharmacist as a process of systematic work and document-
ed in order to optimize the therapeutic results of patients 
who are already undergoing medical care.
The aim of this study was to analyze the influence of 
pharmacotherapeutic follow-up on quality of life of HIV 
positive patients who are starting antiretroviral therapy, 
and are treated by the Pharmaceutical Care program at a 
specialized service in northeast Brazil.
MATERIAL AND METHODS
This is prospective controlled intervention study, 
in which each patient served as his own control, was de-
veloped using Pharmacotherapeutic Follow-up (PTF) of 
patients with STD/HIV treated at an outpatient pharmacy 
at a specialized medical center in Fortaleza, Ceará, during 
the period from November 2008 to August 2010.
The PTF, with a duration of nine months, was based 
on monthly meetings; there was a total of nine meetings 
with each patient, which were carried out in line with the 
Dáder method (Machuca, Fernández-Limos, Faus, 2003), 
and involved the following steps: 1 . invitation to receive 
the service; 2. initial interview; 3. Situational diagnosis; 
4. study phase; 5. global assessment; 6. pharmaceutical 
intervention and 7. evaluation of results.
The patients were invited to participate in the PTF 
when they attended the pharmacy to start antiretroviral 
therapy, which was medically indicated. The study includ-
ed patients who: had never been treated with antiretroviral 
drugs; began therapy during the study period; were aged 
over 18 years; had not participated in any pharmaceutical 
intervention study; and agreed to participate. Exclusion 
criteria were: patients who were not in a condition to reply 
to questions during interviews and pregnant women (who 
were referred to a different unit for specialized health).
The study was approved by the Ethics Committee in 
Research of the Federal University of Ceará - UFC (pro-
tocol number: 191/08). When the invitation was accepted, 
an individual interview was carried out during which ex-
planations of the study were provided and a consent form 
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signed. The interviews were conducted by the pharmacist 
of the health care unit with the help of an academic from 
the Pharmacy course at UFC. The interviewers received 
prior training by the Centre of Studies in Pharmaceutical 
Care (CEATENF-UFC).
The collection of data on sociodemographic (gender, 
age, marital status, education, individual income) and 
clinical variables (time of diagnosis and presence of signs/
symptoms at the start of therapy) was carried out using the 
questionnaire that had been prepared by CEATENF after 
meetings and focus groups. The Drug-Related Problems 
(DRPs) and pharmaceutical interventions were recorded 
and classified according to the Second Consensus of 
Granada (Santos et al., 2004; Sabater et al., 2005). More 
than one problem related to the antiretroviral drugs and 
interventions could be identified for a single patient.
The assessment of quality of life was divided into 
two phases: at the beginning (1st meeting) and at the end 
of PTF (9th meeting), using the instrument of Ware and 
Sherbourne (1992) according to the translation and vali-
dation to Brazilian-portuguese language by Ciconelli et 
al. (1999).
The instrument includes eight domains (physical 
functioning, role limitation due to physical health, bodily 
pain, general health perceptions, vitality, social function-
ing, role limitations due to emotional problems and mental 
health) and, for each area, a score was obtained by apply-
ing a scale measure with values from 0 to 100, where zero 
corresponds to the worst result and one hundred, to the best 
result (Siqueira, 2005).
Data regarding the clinical and socioeconomic pro-
files, DRP and pharmaceutical intervention were entered 
into an Excel 2007 database, and analyzed descriptively, 
represented by tables and/or graphs. For the results regard-
ing quality of life, a comparison between the initial and 
final profiles was carried out using the paired Student’s t 
test, and the Kolmogorov-Smirnov test was used to verify 
the normality of the scores. The Wilcoxon test was used 
for samples with less than 30 individuals that did not pass 
the normality test. The program Sigma Plot, version 10.0, 
was used for the statistical analysis of quality of life, with 
a significance level of 5%.
RESULTS
A total of 47 of the HIV + patients treated at the Unit 
during the study period fulfilled the requirements to par-
ticipate in the project, but one patient died before the end 
of treatment and another abandoned the treatment, only 
returning after the end of the period for the PTF. Excluding 
these losses, the study worked with a sample of 45 patients. 
The clinical and socioeconomic profile of these patients is 
presented in Table I. Most were male (62.2%) with a mean 
age of 37.04 years (SD=11.47), a “single” marital status 
and a schooling level that was “incomplete primary” or 
“complete secondary”. As for individual income, 42.2% 
reported having an income between 1 to 2 minimum 
wages, which at the time of study ranged from R$ 415.00 
to R$ 510.00. Regarding the signs and symptoms, 16 pa-
tients (35.6%) reported, at the time of first interview, that 
they were asymptomatic, and 29 (64.4%) reported already 
showing signs/symptoms of HIV infection. Regarding the 
time of diagnosis, more than half of patients (55.6%) had 
received a diagnosis of HIV infection within the previous 
12 months.
The study identified 643 problems related to anti-
retrovirals. The main problems were “security”, mainly 
referring to the occurrence of adverse reactions (58%, 
n=373) and the “necessity” for drugs, particularly related 
to the non-compliance to treatment/adherence problems 
(27.4%, n=176). Issues that were classified as “effective-
ness”, related to the dose of antiretroviral drugs (in this 
case, underdosing) were also identified (12.9%, n = 83).
There were 590 pharmaceutical interventions during 
the follow-up. Of these, 469 could be classified according 
to Sabater, and were distributed in the following catego-
ries: “intervention regarding dosage” (19.6%, n = 92), 
“change in pharmacological strategy” (13.7%, n = 64) 
and “intervention in the education” of patients (66.7%, 
n = 313). Another 121 interventions were carried out, 
but these did not fit into the Sabater categories and were 
related to referrals to other professionals and support over 
biopsychosocial aspects.
When analyzing the data for question N° 2, which 
deals with the comparative evaluation between the current 
health status and that of one year ago, the most frequent 
response among respondents before the PFT was: “About 
the same as one year ago” (28.9%).
After the pharmacotherapy monitoring, 24 pa-
tients responded: “Much better now than one year ago”, 
(53.3%). Another important fact is that before the follow-
up, some patients (15.6%, n=7) responded to the above 
item as: “Much worse now than one year ago”, while at 
the end of the study, no participant had this response to 
question No. 2 (Figure 1).
The analysis of data from the quality of life ques-
tionnaire domains, considering both symptomatic and 
asymptomatic patients, revealed that the differences 
between the means were statistically significant for all 
the domains. Furthermore, the mean values obtained at 
the 9th meeting were always higher than those from the 1st 
meeting (Figure 2).
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TABLE I - Distribution of socioeconomic and clinical profiles 
of HIV + patients under pharmacotherapeutic follow-up at a 
specialized treatment centera (N = 45)
Variable Frequency Percent (%)
Gender
     Male 28 62.2
     Female 17 37.8
Age 
     20 to 30 years 15 33.3
     30 <age <40 years 15 33.3
     40 <age <50 years 9 20
     50 <age <60 years 4 8.9
     More than 60 years old 2 4.5
Marital Status
     Single 23 51.1
     Married 6 13.4
     Divorced / Separated 5 11.1
     Widower 1 2.2
     Stable Relationship 10 22.2
Education
     Illiterate 1 2.2
     Reading and writing 1 2.2
     Incomplete primary 15 33.3
     Complete primary 8 17.9
     Incomplete high school 2 4.4
     Complete high 14 31.2
     Incomplete higher 2 4.4
     Complete higher 2 4.4
Individual income (in minimum 
wages - mw)
     No income 13 28.9
     <01 mw 4 8.9
     01-02 mw 19 42.2
     02-03 mw 6 13.4
     03-04 mw 1 2.2
     04-05 mw 0 -
     > 05 mw 2 4.4
Diagnosis time   
     Up to 1 year 25 55.6
     1 <time <3 years 10 22.2
     3 <time <5 years 7 15.5
     Unable to provide 3 6.7
Signs / symptoms   
     Asymptomatic 16 35.6
     Symptomatic. 29 64.4
Source: Direct research- a José de Alencar Medical Specialties 
Center, Fortaleza, Ceará, Nov/2008- Aug/2010
FIGURE 2 - Comparison between the mean values  of the 
domains of the quality of life questionnaire for all patients 
before and after the PTF (N = 45), Specialized treatment centera, 
Fortaleza, Ceará, Nov/2008 - Aug/2010. The paired Student t test 
was carried out for all domains. * P <0.05. a the José de Alencar 
Medical Specialties Center.
FIGURE 1 - Distribution of responses to question No. 2 of the 
quality of life questionnaire applied to all patients before and 
after the PFT (n = 45). Specialized treatment centera, Fortaleza, 
Ceará, Nov/2008 - Aug/2010. a the José de Alencar Medical 
Specialties Center.
The data was also analyzed by separating the symp-
tomatic patients from the asymptomatic patients. For 
the asymptomatic patients, the means found for the 9th 
follow-up visit were always higher than or equal to the 
values obtained at the 1st meeting; however, only the do-
main “General Health Perceptions” showed a statistically 
significant difference between the values obtained before 
and at the end of the PTF (p = 0.022).
For the data referring only to symptomatic patients, 
the mean values were also all higher at the end of the PFT 
than during the 1st moment (Table II) and six domains of 
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TABLE II - Distribution of means, medians and standard deviations (SD) obtained for the domains of the quality of life questionnaire 




* p valueBefore the PTF After PTF
Mean Median SD Mean Median SD
Physical Functioning 65.172 75 31.124 81.897 95 23.957 0.005 ª
Role Limitation due to Physical Health 34.483 0 45.520 64.655 100 45.570 0.009 b
Bodily Pain 64.483 74 34.494 76.379 100 34.808 0.076 b
General Health Perceptions 49.979 54 29.504 67.724 77 29.446 0.006 a
Vitality 58.966 60 25.508 68.966 70 18.916 0.033 ª
Social Functioning 73.276 87.5 32.686 82.759 100 24.643 0.167 b
Role Limitation due to Emotional Problems 37.928 0 47.745 64.362 100 46.232 0.005 b
Mental Health 57.793 60 25.603 71.103 72 22.574 0.011 ª
Source: Direct Research Specialized treatment center c, Fortaleza, Ceará, Nov/2008 - Aug/2010. * Level of significance p <0.05. 
a The paired Student t test was carried out. b The Wilcoxon test was carried out. c the José de Alencar Medical Specialties Center
TABLE III - Distribution of means, medians and standard deviations (SD) obtained for the domains of the quality of life questionnaires 
used in the 1st and 9th PTF for patients with one year of diagnosis (n=25) Specialized Treatment Center, Fortaleza, Ceará
Domains
Up to 1 year of diagnosis
* p valueBefore PTF After PTF
Mean Median SD Mean Median SD
Physical Functioning 73.8 80 25.831 91 100 14.361 0.002 a
Role Limitation due to Physical Health 56 75 44.651 78 100 39.078 0.051 b
Bodily Pain 70.72 72 27.923 85.36 100 27.236 0.057 b
General Health Perceptions 58.6 72 28.362 80.92 87 19.278 <0.001 b
Vitality 68 65 21.311 76.4 85 20.079 0.049 a
Social Functioning 80 100 28.868 89 100 22.044 0.216 b
Role Limitation due to Emotional Problems 59.99 100 48.113 79.996 100 38.493 0.016 b
Mental Health 69.12/ 80 21.742 80.08 84 20.037 0.026a
Source: Source: Direct Research Specialized Treatment Centerc, Fortaleza, Ceará, Nov/2008 - Aug/2010. * Level of significance 
p <0.05. a The paired Student t test was carried out. b The Wilcoxon test was carried out. c the José de Alencar Medical Specialties 
Center
the questionnaire had a statistically significant difference 
between the initial and final mean or median: “Physical 
Functioning” (p=0.005); “Role Limitations due to Physi-
cal Health” (p = 0.009); “General Health Perceptions” 
(p=0.006); “Vitality” (p=0.033); “Role limitation due to 
emotional problems” (p=0.005); and “Mental Health” 
(p=0.011).
Regarding the time of diagnosis, separate analyses 
were carried out, separating the patients into three groups. 
The first group included patients who claimed to have up 
to one year of diagnosis of HIV infection. Regarding the 
domains of the applied instrument, at the 9th follow-up 
visit, this group presented means that were higher than at 
the beginning of monitoring (Table III), with statistically 
significant differences between the initial and final means 
and medians for the domains: “Physical Functioning” 
(p = 0.002); “General Health Perceptions” (p<0.001); 
“Vitality” (p=0.049);”Role Limitations due to Emotional 
Problems” (p=0.016); and “Mental Health” (p=0.026). The 
domain “Role limitations due to Physical Health” had a 
borderline p-value.
The second and third groups (that respectively in-
cluded, patients with a diagnosis of more than one year 
but less than three years, and patients with a diagnosis of 
more than three years) had higher mean values at the end 
of the PFT, when compared with baseline values. How-
ever, in both groups, there were no significant differences 
between the initial and final means and medians in any of 
the domains of the quality of life questionnaire.
DISCUSSION
In recent years, the profile of people infected by HIV 
has changed (Nunes et al., 2008, Rodrigues et al., 2010). 
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The profile of the participants of this study presented 
clinical and socioeconomic characteristics similar to those 
observed in other studies (Seidl et al., 2007; Saldanha, An-
drade, Beck, 2009). The majority of patients interviewed 
were male, and the male-to-female ratio was 1.6:1, which 
is in line with a recent survey by the Ministry of Health, 
which revealed that, in Brazil, this ratio has been decreas-
ing over the years and has stabilized at 1.5:1 since 2002 
(Brasil, 2009). Regarding their age, also according to the 
records of the Ministry of Health, the majority of AIDS 
cases reported from 1980 to 2009 was concentrated in the 
age group 25-49 years. The patients enrolled in this study 
had a mean age of 37 years.
The majority of patients had a low level of schooling 
and income, which shows that there is a need to adopt mea-
sures and simple language throughout the development 
of the Pharmaceutical Care program for these patients. 
Regarding marital status, the study had a higher percent-
age of singles.
The profile of the patients in this study partially 
agrees with the profile of patients in the study by Seild et 
al. (2007), which involved 110 HIV + patients. In the study 
by Seild, the number of singles was equal to those who live 
with a spouse or partner, 36.7% for each one.
The significant number of problems related to anti-
retroviral drugs and pharmaceutical interventions during 
the study reinforces the importance of PTF for the detec-
tion, resolution and prevention of problems related to 
therapy and the role of the pharmacist in the planning of 
care and treatment for each patient as part of a multidisci-
plinary team. In this study, problems of adherence to ART 
and adverse reactions were the most common problems 
related to specific pharmacotherapy. These issues hamper 
the clinical management of patients and the achievement 
of positive outcomes and have been observed in several 
other studies (Walsh et al., 2001; Bartlett, 2002; Padua et 
al., 2007; Guimarães et al., 2008). The pharmaceutical in-
terventions were focused on the category “Patient Educa-
tion”, in line with the profile of the patients, and consisted 
of educational measures that stress the importance of drug 
therapy and adherence to it.
The questionnaire translated and validated by 
Ciconelli et al. (1999) to evaluate the quality of life of 
patients in the study was chosen because this type of 
generic instrument can accurately assess all significant 
aspects related to health and show the impact of a disease 
on a particular individual (Ciconelli et al., 1999; Fayers, 
Machin, 2000).
Question No. 2 of the questionnaire assessed current 
health status and baseline status (one year previously), and 
the vast majority of responses had higher values at the end 
of the PTF when compared to those obtained at the first 
visit. This shows that, at the end of the study, most patients 
considered their health to be better than before starting 
the follow-up.
The final means of the eight domains of the question-
naire were always higher than the initial means. At the first 
PTF meeting, the domains “Social Functioning”, “Physical 
Functioning” and “Bodily Pain” had the highest means. At 
the end of PFT, these domains had the best results when 
compared to the other areas.
The study carried out by Romeo et al. (2009) found 
that pharmaceutical interventions during the PTF of HIV+ 
pregnant women were effective and helped reduce symp-
toms due to inadequate pharmacotherapy and contributed 
to the quality of life of patients.
When a distinction was made between asymptomatic 
and symptomatic patients, the latter had better results at 
the end of PTF, with a statistically significant difference 
for six domains, whereas among asymptomatic patients, 
only the domain “General Health Perceptions” was sig-
nificant. This can be attributed to the fact that since they 
did not have any symptoms at the start of ART and during 
follow-up, and because the indication at the initiation of 
therapy was mainly determined by the results of a CD4+ 
cells count, the changes in quality of life were “minimal”, 
since the treatment significantly reduces the progression 
of infection.
In contrast, when analyzing the patients who were 
symptomatic when they started ART and pharmacothera-
peutic follow-up, it is easy to detect the improvement in the 
quality of life from the minimization and / or termination 
of the signs and symptoms after a few months of treatment 
and monitoring. It is worth emphasizing that the group of 
asymptomatic patients was smaller than the symptomatic 
group, which could explain a lack of statistically signifi-
cant changes in the asymptomatic group.
As for the time of diagnosis, cross-sectional studies 
(Reis, 2008; Santos, França Júnior, Lopes, 2007) have 
demonstrated that individuals with a more recent diag-
nosis have lower scores in relation to certain domains of 
the questionnaires used in assessments of quality of life.
In this study, the group of patients with less than a 
year of diagnosis had the lowest scores for quality of life in 
the first meeting, a result that is consistent with other stud-
ies; however, after PTF, the quality of life of these patients 
improved, with statistical differences between the initial 
and final means or medians and statistical validity in five 
domains. This reinforces the idea that PTF contributes to 
improving the quality of life.
It is believed that individuals with a longer time 
of knowledge of the infection are more adapted to the 
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changes resulting from HIV seropositivity (Reis, 2008), 
and present lower changes in the perception of quality of 
life throughout follow-up.
The results obtained in this study point towards a 
positive influence of pharmacotherapeutic follow-up on 
the quality of life of patients with HIV. It must be noted 
that the study population consisted of patients starting 
antiretroviral therapy, and thus represents a more specific 
population.
Furthermore, these satisfactory and significant 
results of the process of care were observed with only 
nine months of follow-up. Some authors report that a 
minimum of 12 months of PTF (Mazroui et al., 2009; 
Clifford et al, 2005), are needed to achieve beneficial 
results on the quality of life. Also, it is important to 
note that since the study was carried out at a specialized 
care center, which fits into the secondary level of health 
care, this suggests that pharmaceutical care programs 
can be more successful at this level of attention. One 
of the possible factors for this success is the facility of 
multidisciplinary access, integration and interaction in 
the planning of care and present and active participation 
of the pharmacist in specialized care.
CONCLUSION
Pharmacotherapeutic follow-up is developed 
through the detection, resolution and prevention of drug-
related problems and by carrying out pharmaceutical 
interventions. The results of this study suggest that PTF 
may be able to contribute to improving the quality of life 
of HIV patients, undergoing early antiretroviral therapy, 
especially for patients who were symptomatic and/or with 
up to one year of diagnosis; these represent important 
target groups for the practice of pharmaceutical care at a 
secondary health care level. However, more researches are 
needed to reinforce the results obtained, including studies 
using control groups.
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